UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers

Therapeutic advances in neurological disorders, 2019-06, Vol.12, p.1756286419854986-1756286419854986

2019

Volltextzugriff (PDF)

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview

Multiple Sclerosis Journal, 2015-03, Vol.21 (3), p.263-281

2015

Volltextzugriff (PDF)

Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper

Multiple Sclerosis Journal, 2016-10, Vol.22 (11), p.1386-1396

2016

Volltextzugriff (PDF)

FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS

Nature medicine, 2014-03, Vol.20 (3), p.272-282

2014

Volltextzugriff (PDF)

Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark

Journal of neurology, 2016-12, Vol.263 (12), p.2484-2493

2016

Volltextzugriff (PDF)

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

Lancet neurology, 2011-04, Vol.10 (4), p.329-337

2011

Volltextzugriff (PDF)

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

Multiple sclerosis, 2012-02, Vol.18 (2), p.143-152

2012

Volltextzugriff (PDF)

Long-term Lymphocyte Counts in Patients with RRMS Treated with Cladribine Tablets 3.5 mg/kg: Total Lymphocytes, B-, and T-cell Subsets (P5.364)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

Lancet neurology, 2010-07, Vol.9 (7), p.740-750

2010

Volltextzugriff (PDF)

Selective and Discontinuous Reduction of B and T Lymphocytes and NK Cells in Patients with Early and Relapsing MS (ORACLE-MS, CLARITY and CLARITY Extension) after Administration of Cladribine Tablets (P5.351)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Effects of Cladribine Tablets on CD4+ T-cell Subsets in the ORACLE-MS Study: Results from an Analysis of Lymphocyte Surface Markers (P1.402)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Survey of diagnostic and treatment practices for multiple sclerosis in Europe

European journal of neurology, 2017-03, Vol.24 (3), p.516-522

2017

Volltextzugriff (PDF)

Gender and autoimmune comorbidity in multiple sclerosis

Multiple sclerosis, 2014-08, Vol.20 (9), p.1244-1251

2014

Volltextzugriff (PDF)

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis

Journal of neuroinflammation, 2012-09, Vol.9 (1), p.215-215, Article 719

2012

Volltextzugriff (PDF)

Effectiveness of Lymphocyte-based Re-treatment Criteria in Minimizing the Incidence of Severe Sustained Lymphopenia during Treatment with Cladribine Tablets 3.5mg/kg (P5.370)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

Journal of neurology, 2013-04, Vol.260 (4), p.1136-1146

2013

Volltextzugriff (PDF)

Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine

Multiple sclerosis, 2016-06, Vol.22 (7), p.944-954

2016

Volltextzugriff (PDF)

Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis

Multiple sclerosis, 2011-01, Vol.17 (1), p.32-42

2011

Volltextzugriff (PDF)

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

CNS drugs, 2021-11, Vol.35 (11), p.1217-1232

2021

Volltextzugriff (PDF)

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial

Lancet neurology, 2010-07, Vol.9 (7), p.672-680

2010

Volltextzugriff (PDF)

Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis

Multiple sclerosis, 2016-06, Vol.22 (7), p.926-934

2016

Volltextzugriff (PDF)

Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab

Multiple sclerosis, 2013-08, Vol.19 (9), p.1226-1229

2013

Volltextzugriff (PDF)

Comparative effectiveness of natalizumab and fingolimod in subgroups of patients with relapsing-remitting multiple sclerosis from three international cohorts (2943)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta

Journal of immunological methods, 2016-03, Vol.430, p.1-9

2016

Volltextzugriff (PDF)

Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients

Multiple sclerosis, 2010-08, Vol.16 (8), p.942-949

2010

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(55)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(44)
Life Sciences & Biomedicine
(37)
Science & Technology
(37)
Neurosciences & Neurology
(32)
Clinical Neurology
(29)
Multiple Sclerosis
(27)
Female
(26)
Male
(25)
Adult
(22)
Neurosciences
(21)
Neurology
(19)
Middle Aged
(18)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Medicin Och Hälsovetenskap
(9)
Magnetic Resonance Imaging
(8)
Multiple Sclerosis - Drug Therapy
(8)
Multiple Sclerosis - Epidemiology
(8)
Multiple Sclerosis, Relapsing-Remitting - Drug Therapy
(8)
Patients
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview

Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper

FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS

Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

Long-term Lymphocyte Counts in Patients with RRMS Treated with Cladribine Tablets 3.5 mg/kg: Total Lymphocytes, B-, and T-cell Subsets (P5.364)

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

Selective and Discontinuous Reduction of B and T Lymphocytes and NK Cells in Patients with Early and Relapsing MS (ORACLE-MS, CLARITY and CLARITY Extension) after Administration of Cladribine Tablets (P5.351)

Effects of Cladribine Tablets on CD4+ T-cell Subsets in the ORACLE-MS Study: Results from an Analysis of Lymphocyte Surface Markers (P1.402)

Survey of diagnostic and treatment practices for multiple sclerosis in Europe

Gender and autoimmune comorbidity in multiple sclerosis

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis

Effectiveness of Lymphocyte-based Re-treatment Criteria in Minimizing the Incidence of Severe Sustained Lymphopenia during Treatment with Cladribine Tablets 3.5mg/kg (P5.370)

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine

Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial

Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis

Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab

Comparative effectiveness of natalizumab and fingolimod in subgroups of patients with relapsing-remitting multiple sclerosis from three international cohorts (2943)

Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta

Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients

Suchergebnisse filtern